TScan Therapeutics, Inc. (TCRX) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts TCRX Hot Sheet
Join SI Premium – FREE
TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q2 EPS of ($0.28), in-line with the analyst estimate of ($0.28). Revenue for the quarter came in at $500 thousand versus the consensus estimate of $1.8 million.
For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Goldman Sachs Assumes Klaviyo Inc (KVYO) at Buy
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
